Evidence map›Paper›PMID 28777084›Full record

ArticleActa crystallographica. Section D, Structural biology2017

The role of conserved surface hydrophobic residues in the carbapenemase activity of the class D β-lactamases.

Marta Toth, Clyde A Smith, Nuno T Antunes, Nichole K Stewart, Lauren Maltz, Sergei B Vakulenko

Open access · greenAbstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Dynamic Gene Clusters Mediating Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  15. ACS infectious diseases · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Carbapenemase OXA-423: A Novel OXA-23 Variant inInfection and drug resistance · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marta TothDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
Clyde A SmithStanford Synchrotron Radiation Lightsource, Stanford University, Menlo Park, California, USA.
Nuno T AntunesDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
Nichole K StewartDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
Lauren MaltzStanford Synchrotron Radiation Lightsource, Stanford University, Menlo Park, California, USA.
Sergei B VakulenkoDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
University of Notre Dame · USStanford University · US

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Resistance to Carbapenem Antibiotics in Acinetobacter baumanniiR01AI114668 · NIAID · UNIVERSITY OF NOTRE DAME · PI BUYNAK, JOHN D, VAKULENKO, SERGEI · 2015 to 2020
$3.1M
NIAID NIH HHS R01 AI114668NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

Carbapenem-hydrolyzing class D β-lactamases (CHDLs) produce resistance to the last-resort carbapenem antibiotics and render these drugs ineffective for the treatment of life-threatening infections. Here, it is shown that among the clinically important CHDLs, OXA-143 produces the highest levels of resistance to carbapenems and has the highest catalytic efficiency against these substrates. Structural data demonstrate that acylated carbapenems entirely fill the active site of CHDLs, leaving no space for water molecules, including the deacylating water. Since the entrance to the active site is obstructed by the acylated antibiotic, the deacylating water molecule must take a different route for entry. It is shown that in OXA-143 the movement of a conserved hydrophobic valine residue on the surface opens a channel to the active site of the enzyme, which would not only allow the exchange of water molecules between the active site and the milieu, but would also create extra space for a water molecule to position itself in the vicinity of the scissile bond of the acyl-enzyme intermediate to perform deacylation. Structural analysis of the OXA-23 carbapenemase shows that in this enzyme movement of the conserved leucine residue, juxtaposed to the valine on the molecular surface, creates a similar channel to the active site. These data strongly suggest that all CHDLs may employ a mechanism whereupon the movement of highly conserved valine or leucine residues would allow a water molecule to access the active site to promote deacylation. It is further demonstrated that the 6α-hydroxyethyl group of the bound carbapenem plays an important role in the stabilization of this channel. The recognition of a universal deacylation mechanism for CHDLs suggests a direction for the future development of inhibitors and novel antibiotics for these enzymes of utmost clinical importance.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsCatalytic DomainCrystallography, X-RayHumansHydrophobic and Hydrophilic InteractionsMolecular Docking SimulationProtein ConformationAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase OXA-143, Acinetobacter baumanniibeta-LactamasescarbapenemaseCarbapenemsantibiotic resistancecarbapenemasecrystal structureenzyme kineticsmechanism of resistance

Identifiers

PMID28777084
PMCPMC5571744
OpenAlexW2740205458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.